The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1365
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Fexofenadine (Allegra) and Fruit Juice

Fexofenadine (Allegra, and others) is the most recent second-generation H1-antihistamine to become available over the counter (OTC). Cetirizine (Zyrtec, and others) and loratadine (Claritin, and others) are already available OTC. Cetirizine can be sedating in usual doses. Loratadine can be sedating in higher-than-usual doses. Fexofenadine remains nonsedating even in higher doses.1

The manufacturer of Zyrtec has responded to this new OTC product with television advertisements drawing attention to the label warning against taking fexofenadine with fruit juice. Many fruit juices such as grapefruit, orange and apple juice are organic anion transporting peptide (OATP) 1A2 inhibitors. OATP1A2 transporters are involved in the absorption of fexofenadine from the gastrointestinal tract. Inhibition of the activity of intestinal OATP1A2 reduces serum concentrations ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1365
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian